A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Study Purpose

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2) - Measurable multiple myeloma (MM) - Eastern Cooperative Oncology Group performance status of 0-1.

Exclusion Criteria:

  • - Condition that confounds the ability to interpret data from the study.
  • - Known active or history of central nervous system (CNS) involvement of MM.
Note: Other protocol-defined inclusion/exclusion criteria apply

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06121843
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bristol-Myers Squibb
Principal Investigator Affiliation Bristol-Myers Squibb
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Arm A: BMS-986393 + Alnuctamab

Experimental: Arm B: BMS-986393 + Mezigdomide

Experimental: Arm C: BMS-986393 + Iberdomide

Interventions

Drug: - BMS-986393

Specified dose on specified days

Drug: - Alnuctamab

Specified dose on specified days

Drug: - Mezigdomide

Specified dose on specified days

Drug: - Iberdomide

Specified dose on specified days

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University of Alabama at Birmingham, Birmingham, Alabama

Status

Recruiting

Address

University of Alabama at Birmingham

Birmingham, Alabama, 35294-3300

Site Contact

Susan Bal, Site 0008

Clinical.Trials@bms.com

205-934-1908

City of Hope Comprehensive Cancer Center, Duarte, California

Status

Not yet recruiting

Address

City of Hope Comprehensive Cancer Center

Duarte, California, 91010

Site Contact

Myo Htut, Site 0028

Clinical.Trials@bms.com

626-256-4673

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Status

Not yet recruiting

Address

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215

Site Contact

Jessica Liegel, Site 0027

Clinical.Trials@bms.com

617-667-9922

Local Institution - 0010, Omaha, Nebraska

Status

Not yet recruiting

Address

Local Institution - 0010

Omaha, Nebraska, 68198

Site Contact

Site 0010

Clinical.Trials@bms.com

855-907-3286

Laura and Isaac Perlmutter Cancer Center, New York, New York

Status

Recruiting

Address

Laura and Isaac Perlmutter Cancer Center

New York, New York, 10016

Site Contact

Jingmei Hsu, Site 0022

Clinical.Trials@bms.com

646-501-4848

New York, New York

Status

Recruiting

Address

Columbia University Irving Medical Center

New York, New York, 10032

Site Contact

Divaya Bhutani, Site 0009

Clinical.Trials@bms.com

646-317-6303

Memorial Sloan Kettering Cancer Center, New York, New York

Status

Recruiting

Address

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Site Contact

Sham Mailankody, Site 0012

Clinical.Trials@bms.com

646-608-3712

Local Institution - 0023, Pittsburgh, Pennsylvania

Status

Withdrawn

Address

Local Institution - 0023

Pittsburgh, Pennsylvania, 15232

Houston, Texas

Status

Recruiting

Address

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030

Site Contact

Krina Patel, Site 0003

Clinical.Trials@bms.com

713-792-6662